In a promising step forward, Oryzon Genomics has enrolled the first patient in “PORTICO”, “a Phase IIb clinical trial assessing vafidemstat as a treatment for Borderline Personality Disorder, at the Vall d’Hebrón Hospital in Barcelona, Spain. The trial is the first of its kind in a real-world BPD population.”
This follows Oryzon presenting favorable final data from their phase IIa clinical trial “REIMAGINE” in July of last year. It will most likely be a long time before Oryzon will present any data on the PORTICO trial, and there are still many steps to be taken before vafidemstat can be approved for public use, but the recent developments out of Spain have been encouraging.
You can read more about the PORTICO clinical trial, from Kezia Parkins of Clinical Trials Arena, here